313 related articles for article (PubMed ID: 27326766)
1. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
Dahlerup JF; Jacobsen BA; van der Woude J; Bark LÅ; Thomsen LL; Lindgren S
Scand J Gastroenterol; 2016 Nov; 51(11):1332-8. PubMed ID: 27326766
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
Stein J; Walper A; Klemm W; Farrag K; Aksan A; Dignass A
Scand J Gastroenterol; 2018 Sep; 53(9):1059-1065. PubMed ID: 30222479
[TBL] [Abstract][Full Text] [Related]
3. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.
Reinisch W; Altorjay I; Zsigmond F; Primas C; Vogelsang H; Novacek G; Reinisch S; Thomsen LL
Scand J Gastroenterol; 2015; 50(10):1226-33. PubMed ID: 25900645
[TBL] [Abstract][Full Text] [Related]
4. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).
Reinisch W; Staun M; Tandon RK; Altorjay I; Thillainayagam AV; Gratzer C; Nijhawan S; Thomsen LL
Am J Gastroenterol; 2013 Dec; 108(12):1877-88. PubMed ID: 24145678
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia.
Derman R; Roman E; Modiano MR; Achebe MM; Thomsen LL; Auerbach M
Am J Hematol; 2017 Mar; 92(3):286-291. PubMed ID: 28052413
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
8. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark.
Pollock RF; Muduma G
Adv Ther; 2018 Dec; 35(12):2128-2137. PubMed ID: 30456520
[TBL] [Abstract][Full Text] [Related]
9. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease.
Nordfjeld K; Andreasen H; Thomsen LL
Drug Des Devel Ther; 2012; 6():43-51. PubMed ID: 22419860
[TBL] [Abstract][Full Text] [Related]
11. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
12. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial.
Gybel-Brask M; Seeberg J; Thomsen LL; Johansson PI
Transfusion; 2018 Apr; 58(4):974-981. PubMed ID: 29424441
[TBL] [Abstract][Full Text] [Related]
14. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A
J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer
Mulder MB; van den Hoek HL; Birnie E; van Tilburg AJP; Westerman EM
Br J Clin Pharmacol; 2019 Feb; 85(2):385-392. PubMed ID: 30393904
[TBL] [Abstract][Full Text] [Related]
17. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
Bhandari S; Kalra PA; Kothari J; Ambühl PM; Christensen JH; Essaian AM; Thomsen LL; Macdougall IC; Coyne DW
Nephrol Dial Transplant; 2015 Sep; 30(9):1577-89. PubMed ID: 25925701
[TBL] [Abstract][Full Text] [Related]
18. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia.
Kalra PA; Bhandari S; Saxena S; Agarwal D; Wirtz G; Kletzmayr J; Thomsen LL; Coyne DW
Nephrol Dial Transplant; 2016 Apr; 31(4):646-55. PubMed ID: 26250435
[TBL] [Abstract][Full Text] [Related]
19. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
20. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
